Elite Pharmaceuticals to Present ELI-200 (SequestOx™) Data at PAINWeek 2017 National Conference
30. August 2017 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) announced today it will present data for ELI-200 at PAINWeek 2017 National...
Elite Pharmaceuticals, Inc. Initiates Pivotal Bioequivalence Fed Study for Reformulated SequestOx™
13. März 2017 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced today that it has initiated pharmacokinetic testing of its...
Elite Pharmaceuticals to Present SequestOx™ Data at the American Pain Society 35th Annual Scientific Meeting
09. Mai 2016 07:30 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) announced today it will present data for SequestOx™ (ELI-200) at the American...
Elite Announces U.S. FDA Priority Review Designation for SequestOx™ NDA
17. März 2016 07:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced that the New Drug Application (NDA) for SequestOXTM...
Elite Pharmaceuticals, Inc. Reports Strong Growth for Third Quarter of Fiscal Year 2016
09. Februar 2016 16:31 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 09, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced results for the quarter ended December 31, 2015, the third quarter...
Elite Pharmaceuticals, Inc. Reports Strong Growth for Second Quarter of Fiscal Year 2016
09. November 2015 16:37 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced results for the quarter ended September 30, 2015, the second...
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
21. Oktober 2015 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Oct. 21, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced positive top-line results from the Phase 3 pivotal trial of...
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
09. Juni 2015 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 9, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP) announced today that it has entered into a sales and distribution licensing...
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse-Deterrent Oxycodone Product ELI-201
03. Dezember 2014 09:55 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence (BE) study for...
Elite Pharmaceuticals Begins Human Abuse Liability Studies for ELI-200
09. Juni 2014 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 9, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced dosing of the first subject in the treatment phase for a human...